CAR-T cells and other cellular therapies for solid tumors: Current challenges and emerging solutions
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e358Keywords:
Immunotherapy, Adoptive, Neoplasms, Tumor Microenvironment, Lymphocytes, Tumor-Infiltrating, Receptors, Chimeric AntigenAbstract
Recent advances in cancer immunotherapy have transformed adoptive cellular therapy, yielding remarkable clinical outcomes in hematological malignancies, whereas its efficacy in solid tumors remains severely limited by the immunosuppressive tumor microenvironment, antigen heterogeneity, and on-target/off-tumor toxicities. To address these challenges, this article reviewed the principal biological and translational barriers hindering solid tumor treatment, examining advanced modalities such as tumor-infiltrating lymphocytes, engineered T-cell receptors, and novel CAR expressing immune cells based on a comprehensive literature search across PubMed and Scopus.
References
1. Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. Overcoming on target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49-62. https://doi.org/10.1038/s41571-022-00704-3
2. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. https://doi.org/10.1126/scitranslmed.aaa0984
3. Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501-21. https://doi.org/10.1038/s41571-024-00903-0
4. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676-80. https://doi.org/10.1056/nejm198812223192527
5. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163(1):507-13.
6. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796): 126-9. https://doi.org/10.1126/science.1129003
7. Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR Jr, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand’Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A* 02+ patients: a phase 1 trial. Nat Med. 2023;29(1):104-14. https://doi.org/10.1038/s41591-022-02128-z
8. Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR‐T therapy for treatment of solid tumor in clinical trials: a meta‐analysis. Dis Markers. 2019;2019:3425291. https://doi.org/10.1155/2019/3425291
9. Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98-110. https://doi.org/10.1016/j.tmrv.2019.01.005
10. Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189-98. https://doi.org/10.1038/s41591-022-01800-8
11. Barros LRC, Couto SCF, Santurio DS, Paixão EA, Cardoso F, Silva VJ, Klinger P, Ribeiro PDAC, Rós FA, Oliveira TGM, Rego EM, Ramos RN, Rocha V. Systematic review of available CAR-T cell trials around the world. Cancers (Basel). 2022;14(11):2667. https://doi.org/10.3390/cancers14112667
12. Ramos RN, Couto SCF, Oliveira TGM, Klinger P, Braga TT, Rego EM, Barbuto JAM, Rocha V. Myeloid immune cells CARrying a new weapon against cancer. Front Cell Dev Biol. 2021;9:784421. https://doi.org/10.3389/fcell.2021.784421
13. Rossetti R, Brand H, Lima SCG, Furtado IP, Silveira RM, Fantacini DMC, Covas DT, Souza LEB. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunother Adv. 2022;2(1):ltac005. https://doi.org/10.1093/immadv/ltac005
14. Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016;1(3):eaag1266. https://doi.org/10.1126/sciimmunol.aag1266
15. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642-62. https://doi.org/10.1038/nrd4663
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Izadora Peter Furtado, Karolina Santos Esteves, Lucas Eduardo Botelho de Souza
This work is licensed under a Creative Commons Attribution 4.0 International License.
